Drug intelligence / Profile preview

CTA-03

Development stage: Unknown
Lead developer: CTCELLS
Modality: Antibody-Based Therapeutics

Overview

CTA-03 is an antibody drug developed by CTCELLS, Inc. It functions as an inhibitor of Myeloid cell surface antigen CD33 (CD33). The drug is currently in the discovery phase of research and development, with its primary indication being Acute Myeloid Leukemia. Its mechanism of action involves targeting and inhibiting CD33, a protein found on myeloid cells, which is relevant in the context of certain cancers.

Other names: CTA-03(Ctcells)

Targets

CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on CTA-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTA-03.

Explore the full profile